Our ambition is to help revolutionise the treatment of disease through the establishment of our NDD approach to drug discovery.
The return on investment for pharma companies has been rapidly declining for decades to a level where it is already below the cost of capital. This is clearly not a sustainable position.
Traditional approaches to drug R&D have not delivered. Despite all of the conventional wisdom regarding a 'target-driven' reductionist approach, the industry is still plagued by major, hugely expensive late-stage clinical failure.
Something is clearly wrong with the industrialised approach to R&D. Pharma companies traditionally take a top down approach to drug discovery, seeking a target without considering the whole of the disease network. Therefore, the disease may fall back on alternative paths or the pathway targeted may only be part of a complex network.
We need new approaches to embrace the inherent complexity of biology.
NDD provides such an approach, enabling a novel and productive method for the discovery of new medicines and enabling advances in areas which have previously proved intractable.
Read more about our process and our powerful in silico NDD platform here.
Read more about our business model and how we maximise value to our shareholders here.